AcroMeta to Enter Ambient Temperature Cellular Logistics Through Strategic Partnership With Macro HRD SG Pte. Ltd.

AcroMeta Group Limited (SGX: 43F) has announced a strategic partnership with Macro HRD SG Pte. Ltd. (Macro), a Singapore-based provider of management consultancy services to the healthcare sector. The partnership, formalized through a non-binding term sheet, is set to give AcroMeta a strategic stake in Macro-ATCLS Pte. Ltd., the entity commercializing Macro's Ambient Temperature Cellular Logistics (ATCLS) technology. This move marks AcroMeta's entry into the cell and gene therapy logistics industry, a market projected to grow at double-digit rates.

The ATCLS technology, licensed by Macro HRD, is designed to transform the transportation and distribution of living cells and temperature-sensitive biological materials by eliminating reliance on conventional cold chains. It uses proprietary ambient-temperature preservation and reactivation technologies, supported by a Gradient Equilibrium Decision Modeling (GEDM) platform for real-time governance and process control. This allows dormant cells to be transported at ambient temperatures and reactivated at the point of use, potentially reducing cost and fragility while expanding geographic reach.

The market opportunity is substantial. Underlying markets cited in project materials range from US$5.2 billion for immune-cell therapy to US$47 billion for organ transplantation. The global cell-and-gene-therapy 3PL market is estimated at US$1.81 billion in 2025, projected to reach US$16.95 billion by 2035 at a 25.1% CAGR. ATCLS estimates a Serviceable Addressable Market (SAM) of approximately US$14.5 billion by 2032, positioning the technology as a potential category-creating solution.

Under the proposed agreement, AcroMeta will have an option to acquire an exclusive licence to deploy ATCLS across agreed territories in Southeast Asia, including the right to appoint sub-licensees. This structure allows AcroMeta to secure exclusive rights in the region and a first right to acquire additional territories, significantly expanding its commercial reach.

Mr Lawrence Toh, Executive Director of AcroMeta Group Limited, said, "This proposed strategic partnership gives us the opportunity to build a position in an industry where cell and gene therapy logistics are expected to grow at double-digit rates in the years ahead. We see this as a natural extension of our strategy to grow our portfolio beyond our core operations, and we’re excited about the potential to build a meaningful presence in bringing this technology into Southeast Asia."

AcroMeta, currently in facility management services, views this as a strategic diversification. The company intends to continue evaluating opportunities that support long-term growth, focusing on disciplined capital allocation. The board has not yet verified the market data provided by Macro's management, as noted in the press release.